SIRT1 and diabetes mellitus: The induction of sirtuin-1 overexpression, specifically in podocytes, or treatment with the specific sirtuin-1 agonist BF175, in OVE26 type 1 diabetic mice, reduced albuminuria and attenuated diabetes-induced podocyte loss and oxidative stress, providing evidence that sirtuin-1 protects against diabetic disease (Hong et al., 2018).